(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 144.73% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Tonix Pharmaceuticals Holding's revenue in 2025 is $10,041,000.On average, 2 Wall Street analysts forecast TNXP's revenue for 2025 to be $80,937,604, with the lowest TNXP revenue forecast at $80,571,370, and the highest TNXP revenue forecast at $81,303,837. On average, 2 Wall Street analysts forecast TNXP's revenue for 2026 to be $722,944,929, with the lowest TNXP revenue forecast at $229,262,171, and the highest TNXP revenue forecast at $1,216,627,687.
In 2027, TNXP is forecast to generate $963,194,105 in revenue, with the lowest revenue forecast at $963,194,105 and the highest revenue forecast at $963,194,105.